Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publicado em
- 15 mai 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment
Valérie Boige, Olivier Bouché, Claire Mulot, Ludovic Evesque, Meher Ben Abdelghani, Jean-Marc Phelip, Laurent Mineur, Marie-Pierre Galais, Anne-Laure Villing, Vincent Hautefeuille et al.
Descritores MeSH
- Colorectal Neoplasms
- Circulating Tumor DNA
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Cetuximab
- Leucovorin
- Female
- Fluorouracil
- Humans
- Male
Veja também
Estudos relacionados
- Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer
- Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer
- Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
- Resultados de Sobrevivência a Longo Prazo de FOLFOXIRI Modified-Plus Cetuximab versus Bevacizumab em Câncer Colorectal de Tipo Selvagem RAS/BRAF: Análise Final do Ensaio DEEPER